These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 26946057)
1. BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial. Schouten PC; Gluz O; Harbeck N; Mohrmann S; Diallo-Danebrock R; Pelz E; Kruizinga J; Velds A; Nieuwland M; Kerkhoven RM; Liedtke C; Frick M; Kates R; Linn SC; Nitz U; Marme F Int J Cancer; 2016 Aug; 139(4):882-9. PubMed ID: 26946057 [TBL] [Abstract][Full Text] [Related]
2. Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy. Schouten PC; Marmé F; Aulmann S; Sinn HP; van Essen HF; Ylstra B; Hauptmann M; Schneeweiss A; Linn SC Clin Cancer Res; 2015 Feb; 21(4):763-70. PubMed ID: 25480832 [TBL] [Abstract][Full Text] [Related]
3. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Vollebergh MA; Lips EH; Nederlof PM; Wessels LFA; Schmidt MK; van Beers EH; Cornelissen S; Holtkamp M; Froklage FE; de Vries EGE; Schrama JG; Wesseling J; van de Vijver MJ; van Tinteren H; de Bruin M; Hauptmann M; Rodenhuis S; Linn SC Ann Oncol; 2011 Jul; 22(7):1561-1570. PubMed ID: 21135055 [TBL] [Abstract][Full Text] [Related]
4. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Gluz O; Nitz UA; Harbeck N; Ting E; Kates R; Herr A; Lindemann W; Jackisch C; Berdel WE; Kirchner H; Metzner B; Werner F; Schütt G; Frick M; Poremba C; Diallo-Danebrock R; Mohrmann S; Ann Oncol; 2008 May; 19(5):861-70. PubMed ID: 18174609 [TBL] [Abstract][Full Text] [Related]
5. BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial. van Rossum AGJ; Schouten PC; Weber KE; Nekljudova V; Denkert C; Solbach C; Köhne CH; Thomssen C; Forstbauer H; Hoffmann G; Kohls A; Schmatloch S; Schem C; von Minckwitz G; Karn T; Möbus VJ; Linn SC; Loibl S; Marmé F Breast Cancer Res Treat; 2017 Dec; 166(3):775-785. PubMed ID: 28822007 [TBL] [Abstract][Full Text] [Related]
6. High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer. Schouten PC; Vollebergh MA; Opdam M; Jonkers M; Loden M; Wesseling J; Hauptmann M; Linn SC Mol Cancer Ther; 2016 Jan; 15(1):190-8. PubMed ID: 26637364 [TBL] [Abstract][Full Text] [Related]
7. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359 [TBL] [Abstract][Full Text] [Related]
8. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. Gluz O; Mengele K; Schmitt M; Kates R; Diallo-Danebrock R; Neff F; Royer HD; Eckstein N; Mohrmann S; Ting E; Kiechle M; Poremba C; Nitz U; Harbeck N J Clin Oncol; 2009 Dec; 27(36):6144-51. PubMed ID: 19901122 [TBL] [Abstract][Full Text] [Related]
9. Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy. Oonk AMM; van Rijn C; Smits MM; Mulder L; Laddach N; Savola SP; Wesseling J; Rodenhuis S; Imholz ALT; Lips EH Ann Oncol; 2012 Sep; 23(9):2301-2305. PubMed ID: 22357256 [TBL] [Abstract][Full Text] [Related]
10. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J; JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826 [TBL] [Abstract][Full Text] [Related]
12. Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group. Eiermann W; Graf E; Ataseven B; Conrad B; Hilfrich J; Massinger-Biebl H; Vescia S; Loibl S; von Minckwitz G; Schumacher M; Kaufmann M; Eur J Cancer; 2010 Jan; 46(1):84-94. PubMed ID: 19879750 [TBL] [Abstract][Full Text] [Related]
13. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Gogas H; Dafni U; Karina M; Papadimitriou C; Batistatou A; Bobos M; Kalofonos HP; Eleftheraki AG; Timotheadou E; Bafaloukos D; Christodoulou C; Markopoulos C; Briasoulis E; Papakostas P; Samantas E; Kosmidis P; Stathopoulos GP; Karanikiotis C; Pectasides D; Dimopoulos MA; Fountzilas G Breast Cancer Res Treat; 2012 Apr; 132(2):609-19. PubMed ID: 22187126 [TBL] [Abstract][Full Text] [Related]
14. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte PF Bone Marrow Transplant; 2003 Feb; 31(4):275-80. PubMed ID: 12621462 [TBL] [Abstract][Full Text] [Related]
15. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. Quintela-Fandino M; López JM; Hitt R; Gamarra S; Jimeno A; Ayala R; Hornedo J; Guzman C; Gilsanz F; Cortés-Funes H J Clin Oncol; 2006 Aug; 24(22):3611-8. PubMed ID: 16877728 [TBL] [Abstract][Full Text] [Related]
16. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. Piccart MJ; Di Leo A; Beauduin M; Vindevoghel A; Michel J; Focan C; Tagnon A; Ries F; Gobert P; Finet C; Closon-Dejardin MT; Dufrane JP; Kerger J; Liebens F; Beauvois S; Bartholomeus S; Dolci S; Lobelle JP; Paesmans M; Nogaret JM J Clin Oncol; 2001 Jun; 19(12):3103-10. PubMed ID: 11408507 [TBL] [Abstract][Full Text] [Related]
17. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401. Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J; J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398 [TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial. Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351 [TBL] [Abstract][Full Text] [Related]
19. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan. Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y; Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]